A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-02-22
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),
and antitumor activity of PF-07260437, a B7-H4 x CD3 bispecific mAb, in participants aged ≥18
years of age with advanced or metastatic breast cancer, ovarian cancer or endometrial cancer.
Adult participants with other advanced or metastatic high B7-H4 expressing tumors may be
considered after discussion with and approval from sponsor.